Active, not recruitingPhase 3NCT05852431

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

Studying Disorder of lipid metabolism

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
89bio, Inc.
Principal Investigator
Teresa Parli, MD, md
89bio, Inc.
Intervention
Pegozafermin(drug)
Enrollment
360 target
Eligibility
22 years · All sexes
Timeline
2023 – 2026

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05852431 on ClinicalTrials.gov

Other trials for Disorder of lipid metabolism

Additional recruiting or active studies for the same condition.

See all trials for Disorder of lipid metabolism →

← Back to all trials